Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Staar Surgical ( (STAA) ) has shared an announcement.
On April 8, 2026, STAAR Surgical reported that preliminary net sales for the first quarter ended April 3, 2026 are expected to exceed $90 million, more than double the $42.6 million recorded in the same quarter of 2025. The company released these unaudited figures ahead of its full quarterly report, expected in early May, as it engages with investors and ophthalmology professionals at a major industry meeting in Washington, D.C.
Management attributed the strong performance primarily to robust demand in China, its largest market, and continued double-digit growth in the Americas, combined with a significantly improved cost structure that is expected to deliver a meaningful improvement in adjusted EBITDA. However, net sales in parts of the Middle East and other EMEA and APAC markets were hurt by geopolitical and macroeconomic headwinds, and the company cautioned that ongoing volatility and potential spillover of these challenges could continue to weigh on regional sales growth.
STAAR noted that the year-over-year comparison benefited from unusually weak first-quarter 2025 sales to China, when the company shipped minimal EVO ICL volumes while distributors reduced excess inventory. As of the end of the first quarter of 2026, distributor inventory levels in China appear to be back within the company’s targeted range to support the refractive market, underscoring a normalization of channel dynamics even as the results remain subject to final review and possible adjustment.
The most recent analyst rating on (STAA) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
The score is held down primarily by deteriorating profitability and negative operating/free cash flow, despite a low-debt balance sheet and high gross margins. Technicals remain weak with the stock below key longer-term moving averages and a negative MACD. The latest earnings call adds partial support due to improving quarterly execution and a stated path toward FY2026 profitability, but limited formal guidance and China/channel risks keep uncertainty elevated.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical Company, based in Lake Forest, California, is a global leader in implantable phakic intraocular lenses used for vision correction, reducing or eliminating the need for glasses or contact lenses. The company has focused on ophthalmic surgery since 1982 and for three decades has designed, developed, manufactured and marketed its proprietary Implantable Collamer Lenses, selling more than 4 million ICLs in over 85 countries.
STAAR’s EVO family of ICLs offers minimally invasive, clinically proven long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens, positioning the firm as a key player in premium refractive surgery solutions. It operates research, development, manufacturing and packaging facilities in California and Switzerland, serving ophthalmic surgeons and patients worldwide.
Average Trading Volume: 1,370,017
Technical Sentiment Signal: Sell
Current Market Cap: $1.04B
For an in-depth examination of STAA stock, go to TipRanks’ Overview page.